Communiqués Theralase Technologies Inc.

Actions

TLT

CA88337V1004

Equipement et technologie médicale avancés

Marché Fermé - Toronto S.E. Autres places de cotation 21:37:31 31/07/2026			Varia. 5j.	Varia. 1 janv.
0,2850 ^CAD	+1,79%		+7,55%	+72,73%

29/05	Theralase Technologies Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
20/05	Theralase Technologies lève 4,8 millions de dollars via un placement privé intermédié	MT

Communiqués

30/06	Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus	NE
16/06	Theralase Technologies : ® Releases Q1 2026 Financial Statements	PU
03/06	Theralase(R) Lists Warrants on the TSXV	NE
29/05	Theralase(R) Releases Q1 2026 Financial Statements	NE
22/05	Theralase Technologies : ® Closes C$4.8 Million Offering	PU
20/05	Theralase(R) Closes C$4.8 Million Offering	NE
06/05	Theralase(R) Announces $4 Million Brokered LIFE Offering	NE
04/05	Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update	NE
13/04	Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study	NE
10/04	Theralase(R) Closes $CAN 2.66 Million Financing	NE
17/03	Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus	NE
10/03	Theralase(R) Closes $1.1 M Non-Brokered Private Placement	NE
09/03	Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer	NE
02/03	Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy	NE
26/02	Online Criticism And Defamation: An Ontario Anti-SLAPP Decision	AQ
20/02	Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress	NE
17/02	Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress	NE
10/02	Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting	NE
04/02	Theralase(R) Provides Update on Bladder Cancer Clinical Study	NE
02/02	Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study	NE
12/01	Canadian Investment Regulatory Organization Trade Resumption - TLT	AQ
12/01	Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer	NE
09/01	Canadian Investment Regulatory Organization Trading Halt - TLT	AQ
23/12	Theralase(R) Closes $1.3 M Non-Brokered Private Placement	NE
12/12	Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing	NE